KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of L-oxiracetam on cognitive function in patients with traumatic brain injury: a multicentre, randomised, double-blind, phase 3 clinical trial.

Tao Liu, Jiao Wang, Zhihao Zhao, Weiwei Jiang, Minzhi Zhang, Yunhu Yu, Yang Liu, Mingqi Liu, Linan Chen, Hengzhu Zhang, Yingbiao Hong, Bohe Li, Rutong Yu, Hongming Ji, Liang Mi, Biao Zhao, Chuanxiang Lv, Chenglong Liu, Jianning Zhang, Rongcai Jiang, LOCATE Trial Investigators

Signal Transduct Target Ther 10(1) 401

PMID41381424
PMCIDPMC12698704
DOI10.1038/s41392-025-02492-5
发表日期2025-12-11
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 other;Fig. 3:森林图/亚组分析图。
摘要

摘要

To assess the efficacy and safety of L-oxiracetam, a novel nootropic agent, in improving cognition in patients with TBI, we performed a multicentre, double-blind, randomized controlled trial in China. Participants aged 18 to 75 years with TBI (Glasgow Coma Scale score of 10 to 15) were recruited from 51 hospitals from 2019 to 2024. Patients were randomly assigned to L-oxiracetam, 4 g/day, oxiracetam 6 g/day, or placebo in 2:2:1. The primary outcome was the change in the Loewenstein Occupational Therapy Cognitive Assessment (LOTCA) score from baseline to 90 days post treatment. Secondary outcomes included changes in additional cognitive evaluations, neurological function, activities of daily living (ADL), and adverse events (AEs). The trial was approved by the China National Medical Products Administration (2016L03521), and registered at Clinicaltrials.gov (NCT04205565) and Chinadrugtrials.org.cn (CTR20192539). Five hundred and ninety patients were included (mean age (SD), 50.9 (14.5); 421 males). The least squares (LS) mean of LOTCA change from baseline to 90 days post treatment was 20.45 (95% confidence interval [CI] 17.23, 23.66) in the L-oxiracetam group, 15.90 (95% CI 12.71, 19.10) in the oxiracetam group, and 11.47 (95% CI 7.75, 15.20) in the placebo group (P value < 0.05 for all groups). The LS mean difference of the L-oxiracetam was significantly higher than the placebo group (8.97, 95% CI 5.69,12.26; P < 0.001; Cohen's d = 0.48 [95% CI: 0.26,0.69]) and the oxiracetam group (4.54, 95% CI 1.85,7.23). Secondary efficacy outcomes did not differ between the L-oxiracetam and oxiracetam groups. The proportion of serious AEs did not differ among the three groups. L-oxiracetam could improve cognitive function in patients with mild-to-moderate TBI. L-oxiracetam might be more efficacious than oxiracetam. No significant safety concerns were reported. Despite limitations such as loss to follow-up, the findings of this study provide important evidence for the clinical management of cognitive dysfunction following TBI. Future studies in real-world clinical settings are warranted to further substantiate the efficacy of L-oxiracetam and oxiracetam.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Patient flow through the trial. Flowchart illustrating the enrollment, screening, randomization, intervention, and follow-up processes for participants in this trial
非 KM Figure
Fig. 2Fig. 2 Column chart of LOTCA scores at baseline, 14 days, and 90 days. The LOTCA scores at days 14 and 90 were significantly higher than baseline in all 3 groups (L-oxiracetam, Oxiracetam, and Placebo). *There was a significant increase in LOTCA compared with the baseline. LOTCA Loewenstein Occupational Therapy Cognitive Assessment
非 KM Figure
Fig. 3Fig. 3 Subgroup analysis of the primary outcome (mean change in LOTCA at 90 days). Models adjusted for age, sex, education, TBI severity, and LOTCA at baseline. There were significant interactions between L-oxiracetam treatment and sex and TBI severity. yr year, TBI Traumatic brain injury
非 KM Figure